Chronic Inflammation After Menopause, What the Research on Shilajit Actually Shows

What is chronic inflammation, and how is it different from a normal immune response?

Inflammation is not inherently bad. A sprained ankle swells because immune cells rush to the area, wall it off, and start repair. That response is fast, visible, and it resolves in days.

Chronic inflammation is a different animal entirely. It is low-grade, it does not resolve, and it runs quietly for months or years without a single visible symptom. Instead of a swollen joint, it shows up as elevated levels of signaling molecules called cytokines, TNF-alpha, IL-6, and IL-1 beta among them, plus a rise in C-reactive protein, a liver protein that spikes in response to those signals.

Why this matters even when nothing hurts

Researchers now treat chronic low-grade inflammation as a driver behind a long list of conditions that show up more often with age, including insulin resistance, cardiovascular disease, and joint degeneration. A woman can carry elevated inflammatory markers for years with no symptom pointing her toward them.

What does the research actually show about inflammation after menopause?

Abildgaard and colleagues published a direct comparison in 2020. They recruited 69 healthy women aged 45 to 60, split into premenopausal and postmenopausal groups, and measured their blood for inflammatory markers side by side.

The difference was clear and statistically significant:

• TNF-alpha: 2.24 pg/mL in postmenopausal women versus 1.91 pg/mL in premenopausal women
• IL-6: 0.45 pg/mL in postmenopausal women versus 0.33 pg/mL in premenopausal women
• High follicle-stimulating hormone, the marker that rises as ovarian function winds down, significantly predicted higher TNF-alpha, IL-1 beta, and IL-6 levels

This is a real, measured human comparison, not an inference from animal data. The researchers also found postmenopausal women carried more exhausted, senescent, and memory T-cell subsets, immune cells that have effectively worn down from years of activity, a separate but related sign of an aging immune system working harder than it used to.

Why does falling estrogen let inflammation rise?

Estrogen is not only a reproductive hormone. It has a documented role regulating immune cell activity, including keeping the production of inflammatory cytokines like TNF-alpha and IL-6 in check.

When estrogen falls, that regulation loosens. A few forces layer on top of each other at the same time:

• Estrogen's direct suppression of inflammatory cytokine production declines along with hormone levels
• Visceral fat tends to increase after menopause, and fat tissue is itself an active source of inflammatory signaling
• The immune system shows measurable signs of accelerated aging around the menopause transition, seen in the T-cell shifts above
• Chronic inflammation and oxidative stress feed each other in a loop, each one worsening the other over time
• Sleep disruption, common during the menopause transition, independently raises inflammatory markers

None of these run in isolation. They stack on top of each other, which is part of why inflammatory markers climb gradually rather than all at once.

What does the human shilajit research show against inflammation?

Niranjan and colleagues ran a 12-week randomized controlled trial in 40 adults with type 2 diabetes, a population studied first because inflammation runs measurably higher in diabetes. Alongside cholesterol improvements, the shilajit group showed a drop in high-sensitivity C-reactive protein, the same marker doctors order to screen for cardiovascular inflammation risk.

The same trial also found a drop in malondialdehyde, an oxidative damage marker, and improved endothelial function, the blood vessel lining's ability to relax and respond normally.

This is one placebo-controlled trial, in one specific population, not a postmenopausal inflammation trial. The honest ceiling is that no trial has measured shilajit's effect on inflammatory markers in postmenopausal women specifically. What it shows is a real, measured drop in a standard inflammation marker in a human trial, using the same fulvic acid mechanism behind shilajit's other research.

Where this connects to shilajit's flagship bone trial

Shilajit's 48-week bone density trial in postmenopausal women was not designed to measure inflammation. It measured nitric oxide, a related vascular marker, rising 50 to 60 percent in the treatment group, one more data point in the same general direction as the diabetes trial's CRP finding, from a different angle.

What has fulvic acid been shown to do at the cellular level?

Chein and colleagues studied fulvic acid's effect on human monocytes, immune cells that trigger inflammation when activated. Fulvic acid reduced COX-2 expression and blocked the release of PGE2, a signaling molecule that drives pain and swelling, by inhibiting NF-kB, a master switch that turns on inflammatory gene activity.

That is the same molecular target ibuprofen and Celebrex work through. The study was conducted in cell cultures in a lab, not in a living person, and it did not test shilajit itself, only isolated fulvic acid.

A separate line of research tested a related fulvic acid compound, CHD-FA, against human gum tissue cells pretreated before bacterial exposure. It significantly reduced interleukin-8, a different inflammatory signal tied to tissue swelling, in a laboratory setting.

The honest gap between cellular mechanism and a finished treatment

Neither of these studies is a human clinical trial for any diagnosed inflammatory condition. What they show is that fulvic acid, the compound family shilajit is built on, hits a real, well-characterized inflammatory pathway in laboratory research, the same one several anti-inflammatory drugs target. That is meaningfully different from proof that shilajit reduces inflammation in a living, postmenopausal woman, and we do not blur the two.

How does an anti-inflammatory drug compare with the fulvic acid research, side by side?

Reading the mechanism next to a familiar drug makes the gap easier to see:

The comparison is not a claim that fulvic acid replaces an anti-inflammatory drug. It is a way to see, side by side, how far the laboratory evidence has come and how far it has not.

What can you realistically do about chronic inflammation after menopause?

Chronic inflammation rarely announces itself with a symptom you can point to. It builds quietly, and it is measured in blood, not felt directly. A few reasonable steps the research above points toward:

• Ask about hsCRP at your next physical, it is a low-cost, widely available blood test most doctors can order
• Prioritize sleep, since disrupted sleep independently raises inflammatory markers regardless of any supplement
• Manage visceral fat where possible, since fat tissue is itself an active source of inflammatory signaling
• Do not treat any single marker or supplement as the whole answer, inflammation, oxidative stress, and hormone decline all move together

Shilajit's fulvic acid is the ingredient behind this mechanism research, sourced from the Altai mountains and lab tested for purity on every batch. Optimum Shilajit is built around that fulvic acid content, though a dedicated inflammation trial in postmenopausal women has not yet been run, in shilajit or in almost any natural compound.